Compare SOUNW & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOUNW | ITRM |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | Ireland |
| Employees | 842 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 24.3M |
| IPO Year | N/A | 2018 |
| Metric | SOUNW | ITRM |
|---|---|---|
| Price | $4.00 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 104.1K | ★ 704.9K |
| Earning Date | 02-27-2025 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,297,000.00 | $390,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $193.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 76.05 | N/A |
| 52 Week Low | $4.84 | $0.30 |
| 52 Week High | $6.16 | $2.10 |
| Indicator | SOUNW | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 30.72 | 25.10 |
| Support Level | $3.95 | $0.44 |
| Resistance Level | $4.80 | $0.37 |
| Average True Range (ATR) | 0.40 | 0.03 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 11.85 | 1.74 |
SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.